COMPANY NEWS


Marksans Pharma Ltd
BSE Code 524404 ISIN Demat INE750C01026 Book Value (₹) 25.68 NSE Symbol MARKSANS Div & Yield % 0.3 Market Cap ( Cr.) 7,665.26 P/E * 64.56 EPS * 2.62 Face Value (₹) 1
* Profit to Earning Ratio
* Earning Per Share
Marksans Pharma receives USFDA approval for Guaifenesin ER Tablets Back
(22 Aug 2023)
Marksans Pharma announced that it has received final approval from the US Food and Drug Administration (“FDA”) for its Abbreviated New Drug Application (ANDA) for Guaifenesin Extended-Release Tablets, 600 mg and 1200 mg (OTC) The Guaifenesin Extended-Release Tablets, 600 mg and 1200 mg (OTC) are bioequivalent to the reference listed drug (RLD), Mucinex Extended-Release Tablets, 600 mg and 1200 mg, of RB Health (US) LLC.

Guaifenesin extended-release tablets help to loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive. The company expects to launch the product immediately.